Drug Profile

VLX 101

Alternative Names: VLX-101

Latest Information Update: 30 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VALANX Biotech
Class Amino acids; Cytokines; Drug conjugates; Immunoconjugates; Immunotherapies
Mechanism of Action Cytokine replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Autoimmune disorders

30 Apr 2025 Preclinical trials in Autoimmune disorders in Austria (Parenteral) (Valanx Biotech pipeline, April 2025)
15 Dec 2022 VLX 101 is available for licensing as of 15 Dec 2022. https://www.valanx.bio/pipeline/
15 Dec 2022 Early research in Autoimmune disorders in Austria (Parenteral) before December 2022 (VALANX Biotech, December 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com